Multilocus genetic risk score for diabetic retinopathy in the Han Chinese population of Taiwan

Wen-Ling Liao¹,², Jang-Ming Lin³, Wen-Lu Chen³, Ming-Chia Hsieh¹,⁴, Chia-Ming Wu⁵, Ya-Wen Chang⁵, Yu-Chuen Huang⁶,⁷ & Fuu-Jen Tsai⁵,⁶,⁷

The aim of this study is to explore the effect of genetic variation on diabetic retinopathy (DR) risk in a Taiwanese population. The logistic regression model was used to evaluate the relationship between DR status and risk factors, including the conventional parameters and genetic risk score (GRS). Candidate single nucleotide polymorphisms (SNPs) in GRS were selected based on previous reports with a combined \( P < 10^{-4} \) (genome-wide association) and \( P < 0.05 \) (meta-analysis). In total, 58 SNPs in 44 susceptibility loci were selected, and four were used to calculate GRS. After adjustment for age, systolic blood pressure, diabetes duration, and HbA1c, the DR risk was 4.95 times higher for patients in the top GRS third tile than for those in the bottom third tile (95% CI = 2.99–8.18; \( P < 0.001 \)). The addition of genetic information improved DR prediction, increasing the area under the curve (AUC) from 0.72 to 0.77 (\( P = 0.0024 \)) and improving the sensitivity of the model such that 40 more subjects were reclassified into DR status. The developed multivariate logistic regression model combining conventional risk factors and the multilocus GRS can predict DR, thus enabling timely treatment to reduce blindness in T2D patients.

Diabetic retinopathy (DR) is a common microvascular complication of diabetes and a leading cause of blindness in adults¹–². The prevalence of DR among type 2 diabetes (T2D) patients is about 22%, and up to 80% of patients suffering from diabetes for over 10 years develop DR. The condition progresses from non-proliferative DR (NPDR) to proliferative DR (PDR) and early detection of NPDR may lead to a 60% reduction in PDR and 83% reduction in blindness³. However, many diabetic patients with mild NPDR are not aware of the condition because it does not usually affect their vision, and, since NPDR does not require treatment, it is difficult to prevent its progression to PDR. As DR is a consequence of diabetes, patients should take general precautions to improve their blood sugar control in order to stop or slow the disease progression, but there are no reliable biomarkers for predicting NPDR and/or its development into PDR. Therefore, it is important to identify risk factors for DR progression, which would enable implementation of timely and effective treatment to reduce blindness in T2D patients.

Previous studies showed that a number of traditional risk factors such as age, gender, diabetes duration, fasting plasma glucose, glycosylated hemoglobin (HbA1c), and systolic blood pressure (SBP) could predict the progression and severity of DR⁴–⁷. Multifocal electroretinogram (mERG) with implicit time (IT) and Z-score, foveal thickness, and blood biomarkers, including lipid components (high- and low-density lipoprotein [HDL and LDL, respectively], cholesterol, and triglycerides [TGs]), apolipoprotein, advanced glycation end products, and cytokines could also be used to predict the DR status⁸–¹⁰. Furthermore, it is established that heredity plays a key role in the pathogenesis of diabetes and its complications¹¹–¹⁴, and familial clustering of DR among T2D patients suggests strong contribution of genetic factors to the risk of developing the disease¹⁵.

¹Graduate Institute of Integrated Medicine, China Medical University, Taichung, 404, Taiwan. ²Center for Personalized Medicine, China Medical University Hospital, Taichung, 404, Taiwan. ³Department of Ophthalmology, China Medical University Hospital, Taichung, 404, Taiwan. ⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan. ⁵Human Genetic Center, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan. ⁶School of Chinese Medicine, China Medical University, Taichung, 404, Taiwan. ⁷Department of Health and Nutrition Biotechnology, Asia University, Taichung, 413, Taiwan. Yu-Chuen Huang and Fuu-Jen Tsai contributed equally. Correspondence and requests for materials should be addressed to F.-J.T. (email: d0704@mail.cmuh.org.tw)
A number of genome-wide association studies (GWASs) and candidate gene association studies have been performed to examine genetic susceptibility to DR in different ethnic populations\cite{10,11,12}. However, a comprehensive composite model that can estimate the combined effect of conventional risk factors and genetic background to predict the occurrence of DR in diabetic patients is limited. Therefore, the aim of this study was to investigate the association between previously reported genetic variants and DR risk, and develop a multifactorial logistic regression model to predict DR in the Han Chinese population of Taiwan.

**Results**

**Characteristics of the study participants.** Among the 1,055 T2D patients enrolled in this replication study, 468 had DR (case) and 587 did not have DR (non-DR, control). The male to female ratios were 1.03 (238/230) for the DR group and 1.13 (311/276) for the control group, indicating no statistically significant difference in gender distribution ($P = 0.492$ by Pearson chi-square test). However, age, diabetes duration, age of onset, HbA1c, SBP, diastolic blood pressure (DBP) in the DR group were significantly higher compared to control ($P < 0.001$ for all parameters; Table 1). Additionally, DR groups had lower eGFR value and high ACR value in limited subjects ($n = 564$ for control and 162 for DR).

**Association between individual single nucleotide polymorphisms and DR risk.** Among the 58 susceptibility single nucleotide polymorphisms (SNPs), the majority (except rs4762 and rs498) passed the Hardy-Weinberg equilibrium (HWE) test ($P < 0.05$). For most of the passed SNPs (except rs1801282, rs487083, rs7903146, rs10501943, rs3742872, and rs13306430), minor allele frequency (MAF) exceeded 5% and were similar to those in Han Chinese from Beijing (NCBI GRCh37.p13 assembly) according to the dbSNP website (based on 1000 Genomes project; https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) (Table S1). None of the 58 susceptibility SNPs showed statistical significance in the additive model after Bonferroni correction.

Then, we genotyped/imputed all SNPs located in 44 susceptibility genes; among them, 93 had $P < 0.05$ in the additive model (Table S2). After applying all selection criteria, including $P \geq 0.05$ in the HWE test, MAF $>0.05$, imputation info $\geq 0.4$, and $P < 5.38 \times 10^{-4}$ after Bonferroni correction, four SNPs, rs4748644, rs11101385, rs61893374, and rs142644390, were proved significant in the additive models ($P = 3.81E-04, 1.11E-05, 2.73E-06, and 1.63E-05$, respectively). The identified SNPs are located in the PLXDC2 (Plexin domain-containing 2), ARHGA22 (Rho GTPase-activating Protein 22), CNTN5 (Contactin 5), and FMN1 (Formin 1) genes, respectively (Table 2).

**Cumulative effect of the four genetic loci on the DR risk.** To build the model, we first calculated the multiplex genetic risk score (GRS) for each individual. The cumulative effect of the four significant SNPs was assessed by counting the number of risk genotypes in each individual, and the weighted GRS was calculated based on the logarithm odd ratio (OR) of the susceptibility SNPs. The mean number of risk alleles was $3.24 \pm 1.07$ (range 0–6), and the mean weighted GRS was $3.22 \pm 0.99$ (range 0–6.32) in the derivation sample. The distribution of risk alleles and weighted GRS is shown in Figure S1. All patients were divided into three groups based on the number of risk alleles. The data indicated that the DR risk increased with the number of risk genotypes ($P = 5.98 \times 10^{-12}$; Cochran-Armitage Trend test). Compared with individuals in the lowest range of weighted GRS, the ORs with 95% confidence intervals (CIs) for those in the middle and high range were 2.14 (1.22–3.74), 2.28 as screen positive and 2.28 as screen negative.

**Assessment of the discriminatory ability of models in different datasets.** To assess the discriminatory ability of the models, the model obtained from the derivation sample was applied to the test sample and validation sample and the AUC was determined for all datasets. The model showed a similar discrimination
ability in the test sample (AUC = 0.744 [95% C.I. = 0.700, 0.787] (Fig. 1B)) compared to in the derivation dataset (AUC = 0.77 [95% C.I. = 0.729–0.811]; P = 0.3926). However, the AUC value decreased when the best model was applied to the validation sample (AUC = 0.662 [95% C.I. = 0.601, 0.722]), and the difference between the two AUC values was significant (P = 0.0039) (Figure S2).

Table 1. Demographics of the study population. Values are presented as N (%). Abbreviation: T2D, type 2 diabetes; DR, diabetic retinopathy; DM duration: diabetes mellitus duration; HbA1c: hemoglobin A1c; SBP/DBP: systolic/diastolic blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; eGFR: estimated glomerular filtration rate; ACR: urine albumin creatinine ratio; Ref., reference. *Results from limited subjects (N = 564 and 162 for T2D control and DR, respectively). #Represent P value less than 0.05.
vs. 12.1% and 12.1%, respectively). SNPs rs4838605, rs11101355, and rs11101357 in the respective risk genotypes were shown in Table 2.

GRS, Genetic risk score; Q, quantile; Ref., reference. The genetic risk score was calculated based on 4 SNPs. The type 2 diabetes; DR, diabetic retinopathy; OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; Multivariate association between conventional, genetic, and diabetic retinopathy. Abbreviation: T2D, Table 3.

The addition of the genetic information to the conventional variables improved the discrimination ability for DR, increasing the AUC from 0.721 to 0.770. Furthermore, the sensitivity of model was increased after addition of OR calculation was conducted according to the defined risk alleles (Var/Ref).

In the present study, we investigated the DR risk among the Taiwanese population according to genetic variants identified by GWASs and meta-analysis, and built a prediction model. In the 44 replicated genes, four SNPs were identified to be associated with the DR risk in our population. Furthermore, a GRS based on the number of risk alleles from these four SNPs was calculated for each individual, and an independently cumulative genetic effect was identified by GWAS and meta-analysis, and showed nominally significant (P < 0.05) association with severe NPDR or history of panretinal photocoagulation) for T1D patients. In the present study, rs4748644 was not linked to rs1571942 and rs12219125 (r² = 0.045 for both; Table S4) and showed a different MAF (48.50% vs. 12.1% and 12.1%, respectively). SNPs rs4838605, rs11101355, and rs11101357 in the ARHGAP22 gene

Table 2. Association between genetic SNPs and DR status among Taiwanese population. Abbreviations: SNP, single nucleotide polymorphism; Chr., chromosome; DR, diabetic retinopathy; OR, odds ratio; CI, confidence interval. The genetic risk score was calculated based on 4 SNPs. The respective risk genotypes were shown in Table 2.

Table 3. Multivariate association between conventional, genetic, and diabetic retinopathy. Abbreviation: T2D, type 2 diabetes; DR, diabetic retinopathy; OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure; GRS, Genetic risk score; Q, quantile; Ref., reference. The genetic risk score was calculated based on 4 SNPs. The respective risk genotypes were shown in Table 2.

Discussion
In the present study, we investigated the DR risk among the Taiwanese population according to genetic variants identified by GWASs and meta-analysis, and built a prediction model. In the 44 replicated genes, four SNPs were identified to be associated with the DR risk in our population. Furthermore, a GRS based on the number of risk alleles from these four SNPs was calculated for each individual, and an independently cumulative genetic effect was identified by GWASs and meta-analysis, and showed nominally significant (P < 0.05) association with severe NPDR or history of panretinal photocoagulation) for T1D patients. In the present study, rs4748644 was not linked to rs1571942 and rs12219125 (r² = 0.045 for both; Table S4) and showed a different MAF (48.50% vs. 12.1% and 12.1%, respectively). SNPs rs4838605, rs11101355, and rs11101357 in the ARHGAP22 gene
were identified as associated with DR in Han Chinese and Caucasian patients with both T1D and T2D. Rho GTPase-activating protein encoded by the ARHGAP22 gene is known to be involved in insulin response mechanisms regulating endothelial cell migration and cancer metastasis. In the present study, rs11101385 was highly linked to the reported ARHGAP22 SNPs (rs4838605, rs11101355, and rs11101357; $r^2 = 0.712, 0.8, \text{and } 0.8$, respectively; Table S4), with MAF ranging from 10.24% to 16.16% in the Taiwanese population. A previous GWAS identified CNTN5 and FMN1 as DR susceptibility genes among Mexican Americans: rs10501943 ($P = 2.53 \times 10^{-4}$) mapped to CNTN5 intron regions on chromosome 11q22 and rs10519765 ($P = 6.21 \times 10^{-5}$) mapped to FMN1 intron regions on chromosome 15q13 were found associated with severe DR. In the present study, we identified other SNPs, rs61893374 in the CNTN5 gene and rs142644390 in the FMN1 gene as associated with DR in the Taiwanese population. These SNPs showed low linkage with those reported for Mexican Americans ($r^2 = 0.007$ for rs61893374 vs. rs10501943 in CNTN5 and $r^2 = 0.003$ for rs142644390 vs. rs10519765 in FMN1; Table S4) and had different MAFs (11.7% for rs61893374 vs. 4.9% for rs10501943 in CNTN5, and 11.2% for rs142644390 vs. 8.3% for rs10519765 in FMN1). These results indicate that the selected genes with critical biological functions play an important role in DR development in the Taiwanese population.

Our study has both strengths and limitations. In previous GWASs on DR, none of the regions reached genome-wide statistical significance. The limitations of those studies include modest sample size by GWAS standards, heterogeneous phenotypes (PDR, NPDR, and diabetic macular edema), and poor DR standardization. Our study has several strengths. First, all participants, who were unrelated Han Chinese from Taiwan, underwent exhaustive ophthalmological examination following detailed protocols for both non-DR and DR patients, which limited chances of misclassification. Second, the genetic markers we selected were based on previous studies and all the genetic markers have been reported to be relevant to mechanisms of T2D or DR development. Therefore, these genetic markers represented robust and replicated variants for DR. Third, the difference in allelic frequencies for the four SNPs between the two groups ranged from 7.6% to 20.7% (sample size, 587 vs. 468 for T2D controls and DR cases, respectively) in the current study, thereby raising the statistical power for selecting the appropriate genetic markers of DR risk to over 96%.

We also recognized several limitations in the present study. First, not all of the suggested risk factors such as mfERG, foveal thickness, and certain blood biomarkers (cytokines) could be evaluated in the present study because the relevant information was not collected at the beginning of the study. Second, the cross sectional study design was used in current study. It is necessary to conduct a long-term follow-up evaluation of non-DR T2D patients who carry the risk genotypes to determine DR susceptibility depending on the identified SNPs and prediction model. Third, the AUC value of the model and PPV in the validation sample was decreased compared to that in the derivation sample. Additionally, inconsistency of the association for the genetic variants chosen for GRs was observed in the validation sample. This could be due to several reasons, including the small sample size, the self-reported DR status, and the fact that more participants had diabetic nephropathy ($\text{eGFR} < 90\text{ mL/min/1.73 m}^2$) in the validation sample.

In conclusion, we analyzed the association between a panel of genetic variants and the DR risk and developed a multivariate logistic regression model to predict DR in the Taiwanese population. Confirmatory studies in a cohort of a larger size should be performed in the near future to validate our model.
Methods

Study participants for derivation population. The study involved 1,055 T2D patients 20 years and older, who were recruited from the China Medical University Hospital (CMUH), Taichung, Taiwan. Diabetes was diagnosed based on medical records and fasting plasma glucose levels according to the American Diabetes Association Criteria. Patients with type 1 diabetes (T1D), gestational diabetes, and maturity onset diabetes of the young (MODY) were excluded from this study. The participants were of Han Chinese ethnicity characteristic for 98% of the population in Taiwan. All T2D patients underwent complete ophtalmologic testing, including corrected visual acuity, fundoscopic examination, and fundus photography. An expert ophthalmologist graded DR according to the International Clinical DR Disease Severity Scale proposed by the American Academy of Ophthalmology. The whole groups of subjects were randomly assigned to a derivation set (n = 528) and a test set (n = 527) at a 1:1 ratio. The two databases were found to be compatible (Table S5).

Study participants for validation. Another group of 542 T2D patients from three different hospitals, including CMUH, ChangHua Christian Hospital (CCH), and Taiwan Biobank, were selected for validation. The DR status was self-reported by the subjects. The characteristics of 95 DR and 447 non-DR patients are presented in Table S6.

The study was approved by the CMUH and CCH Institutional Review Board and informed consent was obtained from all participants. We confirm that all experiments of the study were performed in accordance with relevant guidelines and regulations.

Power calculation. With regard to the sample size, we estimated that for a type 1 error of 5% and a power of 80%, a total of 511 participants would be needed to detect an OR of 2.0 for a dependent and an independent variable both with a prevalence of 0.2. Thus, the sample size was sufficient to test small effect sizes given that the prevalence of the corresponding DR was not too low. G*Power Version 3.1.7 was used to algorithm described by Hsieh et al. Table S7 was presented the sample size calculation based on different conditions.

Data collection. Data regarding age, gender, age at T2D diagnosis, and ocular history were collected from questionnaires. For each patient, SBP and DBP, waist and hip circumferences, and body mass index were determined, and blood samples were collected by venipuncture for genomic DNA isolation and serological tests, including fasting glucose and HbA1c, at the time of enrollment in the study.

Genetic marker selection and genotyping/imputation. All of the genetic markers were selected based on previous reports. The inclusion criteria of candidate SNPs were set as a combined P < 10^-4 for GWAS and a P < 0.05 for meta-analysis. A total of 58 SNPs in 44 susceptibility loci were evaluated in our study (details are summarized in Table S1). Furthermore, we performed genotyping or imputation for all the SNPs in our genetic marker selection. Genotyping data were quality-controlled, and SNPs were excluded from further analysis if: (1) MAF was less than 5% in non-DR T2D controls, (2) the total call rate was less than 95% for both DR and control patients, or (3) an SNP significantly departed from HWE proportions for controls (P < 0.05). For the untyped SNPs, genotype imputation was performed according to the methodology of Howie et al. implemented in impute v2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html). The panel from 1,000 Genomes Project was used as reference for imputation, and the software chose the best customized reference set for each individual. SNPs with low imputation quality (info < 0.4) and those in the same gene showing strong disequilibrium with each other (D’ > 0.8) were excluded from further analysis. Each SNP was tested for association with DR in an additive model by multivariable logistic regression analysis after adjustment for T2D duration and HbA1c level. The genotypes were coded in the additive model as “0” for non-risk allele homozygotes, “1” for heterozygotes, and “2” for risk allele homozygotes. A total of 93 SNPs in 24 genetic loci were identified (Table S2); among them, four showed statistical significance after Bonferroni correction (cut-off P value for Bonferroni correction = 0.05/93 = 5.38 × 10^-4). The flow chart for genetic marker selection is presented in Figure S3.

Statistical Analysis. Analyses were performed using the logistic regression model to evaluate the relationship between DR status and the following of two groups of factors: conventional parameters and genetic markers. These factors were selected based on literature review and information collected from databases. Conventional parameters included age, sex, DM duration, SBP, DBP, and serological markers (such as fasting plasma glucose, HbA1c, and lipid markers (HDL, LDL, cholesterol, and TGs)). For the genetic markers, the four significant SNPs that passed the selection process described above were used to calculate the weighted GRS. The GRS for each individual was calculated based on the number of risk alleles weighted by the effect size (logarithm of ORs) according to the following equation:

\[
\text{weighted GRS} = \frac{4}{3.462} \times [(\text{ARHGAP22}_{rs11101385}_{Risk} \times 0.932) + (\text{FMN1}_{rs142644390}_{Risk} \times 1.077) + (\text{PLXDC2}_{rs4748644}_{Risk} \times 0.451) + (\text{CNTN5}_{rs6189374}_{Risk} \times 1.002)].
\]

The weighted GRSs were divided into three equal groups to calculate the cumulative effect. The weighted GRS in the prediction model was calculated from the derivation sample and applied to test/validation samples.

The ORs with 95% CIs of predictor variables were estimated using logistic regression models to develop a best model of DR risk in the derivation sample and to assess the model's discrimination ability in the test sample and validation sample. We used three steps to select independent variables that result in a “best” model. First, we conducted a univariable analysis of each variable. Second, we selected variables P < 0.05 as a candidate in the multivariable model. Third, we constructed a multivariable model with candidate variables by the backward selection method. To determine the impact of genetic factors, two models were compared, including the model with “conventional” variables (age, diabetes duration, HbA1c, and SBP) and the model with conventional and GRS. The difference between AUC values from models was evaluated by Z statistics.
Furthermore, the total risk score of the DR risk was calculated for each subject based on the regression coefficients of all conventional parameters and GRS in the best model. Receiver operating characteristic (ROC) curves were generated to quantify the predictive accuracy of the models, and the AUC was used to assess the discriminatory ability of the models. To assess discrimination, the model obtained from the derivation sample was applied to the test sample and validation sample and the AUC was determined for all samples. All statistical analyses were performed using SPSS software, v. 12.0 for Windows (IBM, Armonk, NY, USA).

References
1. Caldwell, R. B. et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiologic mechanisms and treatment perspectives. *Diabetes Metab Res Rev* **19**, 442–455, https://doi.org/10.1002/dmrr.415 (2003).
2. Taylor, H. R. & Keeffe, J. E. World blindness: a 21st century perspective. *Br J Ophthalmol* **85**, 261–266 (2001).
3. Liu, W. J. et al. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan. *Diabetic medicine: a journal of the British Diabetic Association* **20**, 727–733 (2003).
4. Karoli, R., Fatima, J., Shukla, V., Garg, P. & Ali, A. Predictors of diabetic retinopathy in patients with type 2 diabetes who have normoalbuminuria. *Annals of medical and health sciences research* **3**, 536–540, https://doi.org/10.1016/j.amsr.2014.02.022 (2013).
5. Maghbooli, Z., Pasalar, P., Keshetkar, A., Farzadfar, F. & Larjani, B. Predictive factors of diabetic complications: a possible link between family history of diabetes and diabetic retinopathy. *Journal of diabetes and metabolic disorders* **13**, 55, https://doi.org/10.1186/2251-6581-13-55 (2014).
6. Cheng, Y. J. et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. *Diabetes care* **32**, 2027–2032, https://doi.org/10.2337/dc09-0440 (2009).
7. Xu, J. et al. Prevalence and risk factors for diabetic retinopathy: the Beijing Communities Diabetes Study 6. *Retina* **32**, 322–329, https://doi.org/10.1097/IAE.0b013e3182425f11 (2012).
8. Anitha, B., Sampathkumar, R., Balasubramanym, M. & Rema, M. Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects. *Journal of diabetes and its complications* **22**, 261–266, https://doi.org/10.1016/j.jdic.2007.05.005 (2008).
9. Saxena, R., Singh, D., Saklani, R. & Gupta, S. K. Clinical biomarkers and molecular basis for optimized treatment of diabetic retinopathy: current status and future prospects. *Eye and brain* **3**, 1–13. https://doi.org/10.4172/2155-9618.1666 (2016).
10. Goldberg, R. B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. *The Journal of clinical endocrinology and metabolism* **94**, 3171–3182, https://doi.org/10.1210/jc.2008-2534 (2009).
11. Lim, L. S. & Wong, T. Y. Lipids and diabetic retinopathy. *Expert opinion on biological therapy* **12**, 93–105, https://doi.org/10.1517/17173998.2012.641531 (2012).
12. Sobrin, L. et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate Gene Association Resource (CARe). *Investigative ophthalmology & visual science* **52**, 7593–7602, https://doi.org/10.1167/iovs.11-7510 (2011).
13. Rema, M., Saravanan, G., Deepa, R. & Mohan, V. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. *Diabetic medicine: a journal of the British Diabetic Association* **19**, 910–916 (2002).
14. Imperatore, G. et al. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. *Pima Diabetes Genes Group. Diabet. 47*, 821–830 (1998).
15. Hampton, B. M., Schwartz, S. G., Brantly, M. A. Jr. & Flynn, H. W. Jr. Update on genetics and diabetic retinopathy. *Clinical ophthalmology* **9**, 2175–2193, https://doi.org/10.2147/OPTH.S394508 (2015).
16. Kuo, J. Z., Wong, T. Y. & Roter, J. I. Challenges in elucidating the genetics of diabetic retinopathy. *JAMA ophthalmology* **132**, 96–107, https://doi.org/10.1001/jamaophthalmol.2013.5024 (2014).
17. McAuley, A. K. et al. Replication of genetic loci implicated in diabetic retinopathy. *Investigative ophthalmology & visual science** 55**, 1666–1671, https://doi.org/10.1167/iovs.13-13559 (2014).
18. Fu, Y. P. et al. Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans from Starr County, Texas. *Journal of ophthalmology* **2010**, https://doi.org/10.1155/2010/861291 (2010).
19. Huang, Y. C. et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. *Ophthalmology* **118**, 642–648, https://doi.org/10.1061/j.optha.2010.07.020 (2011).
20. Hosseini, S. M. F. et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. *Human genetics* **134**, 247–257, https://doi.org/10.1007/s00439-014-1517-2 (2015).
21. Ding, Y., Hu, Z., Yuan, S., Xie, P. & Liu, Q. Association between transcription factor β-like 2 rs9703146 polymorphism and diabetic retinopathy in type 2 diabetes mellitus: A meta-analysis. *Diabetes & vascular disease research* **12**, 436–444, https://doi.org/10.1186/s12980-015-0127-5 (2015).
22. Larance, M. et al. Global phosphoproteomics identifies a major role for AKT and 14-3-3 in regulating EDC3. *Molecular & cellular proteomics* **9**, 682–694, https://doi.org/10.1074/mcp.M900345-MCP200 (2010).
23. Sheu, W. H. et al. Genome-wide association study in a Chinese population with diabetic retinopathy. *Human molecular genetics* **22**, 3165–3173, https://doi.org/10.1093/hmg/ddt161 (2013).
24. Diagnosis and classification of diabetes mellitus. *Diabetes Care* **36** Suppl 1, S67–74, https://doi.org/10.2337/dc13-S067 (2013).
25. Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology** 110**, 1677–1682, https://doi.org/10.1016/j.ophtha.2003.03.004-75-5 (2003).
26. Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power* 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behavior research methods* **39**, 175–191 (2007).
27. Faul, F., Erdfelder, E., Buchner, A. & Lang, A. G. Statistical power analyses using G*Power 3: tests for correlation and regression analyses. *Behavior research methods** 41**, 1119–1160, https://doi.org/10.3758/BRM.41.4.1119 (2009).
28. Hisch, F. Y., Bloch, D. A. & Larsen, M. A simple method of sample size calculation for linear and logistic regression. *Statistics in medicine* **17**, 1623–1634 (1998).
29. Hallman, D. M. et al. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. *Diabetes* **56**, 1167–1173, https://doi.org/10.2337/db06-1337 (2007).
30. Zhang, Z. et al. Association of chemokine ligand 5/chemokine receptor 5 gene promoter polymorphisms with diabetic microvascular complications: A meta-analysis. *Journal of diabetes investigation* **7**, 212–218, https://doi.org/10.1111/jdi.12397 (2016).
31. Wang, W., He, M. & Huang, W. Association of monocyte chemoattractant protein-1 gene 2518A/G polymorphism with diabetic retinopathy in type 2 diabetes mellitus: A meta-analysis. *Diabetes research and clinical practice* **120**, 40–46, https://doi.org/10.1016/j.diabres.2016.07.016 (2016).
32. Luo, S., Wang, F., Shi, C. & Wu, Z. A Meta-Analysis of Association between Methylenetetrahydrofolate Reductase Gene (MTHFR) 677C/T Polymorphism and Diabetic Retinopathy. *International journal of environmental research and public health* **13**, https://doi.org/10.3390/ijerph13080806 (2016).
33. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating curves. *BMC Biometrics* 15, 163, https://doi.org/10.1186/s12848-015-0155-3 (2015).
34. Fan, W. Y. & Liu, N. P. Meta-analysis of association between K_{699}E polymorphism of the ICAM-1 gene and retinopathy in type 2 diabetes. *International journal of ophthalmology* 8, 603–607, https://doi.org/10.3989/ijjo.2222-3959.2015.03.30 (2015).
35. Meng, N., Zhang, Y., Li, H., Ma, J. & Yu, Y. Association of tumor necrosis factor alpha promoter polymorphism (TNF-α 238 G/A and TNF-α 308 G/A) with diabetic mellitus, diabetic retinopathy and diabetic nephropathy: A meta-analysis. *Current eye research* 39, 194–203, https://doi.org/10.3109/027168313.2013.834942 (2014).
36. Liu, L. et al. TGF-beta1 gene polymorphism in association with diabetic retinopathy susceptibility: a systematic review and meta-analysis. *PloS one* 9, e94160, https://doi.org/10.1371/journal.pone.0094160 (2014).
37. Han, L. et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies. *Journal of diabetes research* 2014, 805801, https://doi.org/10.1155/2014/805801 (2014).
38. Yuan, Y. et al. Meta-analysis of functional roles of DCCCOLOs. *Neuroinformatics* 11, 47–63, https://doi.org/10.1007/s12021-012-9165-y (2013).
39. Qi, M., Xiong, W., Liao, H. & Li, F. VEGF -634 G > C polymorphism and diabetic retinopathy risk: a meta-analysis. *Gene* 518, 310–315, https://doi.org/10.1016/j.gene.2013.01.018 (2013).
40. Zhao, S., Li, T., Zheng, B. & Zheng, Z. Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms in association with diabetic retinopathy susceptibility: A meta-analysis. *Ophthalmic genetics*, https://doi.org/10.3109/13816810.2012.673598 (2012).
41. Yuan, D. & Liu, Q. Association of the receptor for advanced glycation end products gene polymorphisms with diabetic retinopathy in type 2 diabetes: a meta-analysis. *Acta ophthalmologica. Journal international d’ ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde* 227, 223–229, https://doi.org/10.11159/000335628 (2012).
42. Niu, W. & Qi, Y. An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. *Diabetes research and clinical practice* 95, 110–118, https://doi.org/10.1016/j.diabres.2011.10.009 (2012).
43. Ma, J. et al. Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene and diabetic retinopathy in Caucasians and Asians. *Molecular vision* 18, 2352–2360 (2012).
44. Tian, C., Fang, S., Du, X. & Jia, C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. *Diabetologia* 54, 803–811, https://doi.org/10.1007/s00125-010-2046-5 (2011).
45. Zhou, J. B. & Yang, J. K. Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis. *Acta diabetologica* 47, 187–193, https://doi.org/10.1007/s00592-009-0160-1 (2010).
46. Zhao, T. & Zhao, J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. *Diabetes research and clinical practice* 90, 45–53, https://doi.org/10.1016/j.diabres.2010.05.029 (2010).
47. Abbary, S., Hewitt, A. W., Burdon, K. P. & Craig, J. E. A systematic meta-analysis of genetic association studies for diabetic retinopathy. *Diabetes* 58, 2137–2147, https://doi.org/10.2337/db09-0059 (2009).
48. Wiwanitkit, V. Angiotensin-converting enzyme gene polymorphism is correlated to diabetic nephropathy and diabetic retinopathy—a meta-analysis. *Journal of diabetes and its complications* 22, 144–146, https://doi.org/10.1016/j.jdiacomp.2006.09.004 (2008).
49. Zintzaras, E., Chatzoulis, D. Z., Karabatsas, C. H. & Stefanidis, I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. *Journal of human genetics* 50, 267–275, https://doi.org/10.1038/jhg.2005.50 (2005).
50. Fujisawa, T. et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin 1-converting enzyme gene with diabetic nephropathy and retinopathy. *Diabetologia* 41, 47–53, https://doi.org/10.1007/s001250050868 (1998).
51. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. *G3* 1(1), 457–470, https://doi.org/10.1534/g3.111.001918 (2011).
52. Ding, K., Bailey, K. R. & Kullo, I. J. Genotype-informed estimation of risk of coronary heart disease based on genome-wide association data linked to the electronic medical record. *BMC Cardiovascular disorders* 11, 66, https://doi.org/10.1186/1471-2261-11-66 (2011).
53. Hosmer, D. W. L. S. Applied logistic regression, (Wiley-Interscience Publication, 2000).
54. Lin, C. C. et al. Development and validation of a risk prediction model for end-stage renal disease in patients with type 2 diabetes. *Scientific reports* 7, 10177, https://doi.org/10.1038/s41598-017-09243-9 (2017).
55. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44, 837–845 (1988).
56. Seddon, J. M., Reynolds, R., Yu, Y. & Rosner, B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. *JAMA ophthalmology* 131, 448–455, https://doi.org/10.1001/jamaophthalmol.2013.2578 (2013).
57. Seddon, J. M., Reynolds, R., Yu, Y., Daly, M. J. & Rosner, B. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. *Ophthalmology* 118, 2203–2211, https://doi.org/10.1016/j.ophtha.2011.04.029 (2011).
58. Seddon, J. M. et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. *Investigative ophthalmology & visual science* 50, 2044–2053, https://doi.org/10.1167/iovs.08-3064 (2009).

**Acknowledgements**
This work was supported in part by research grants from the Biosignature project, Academia Sinica, Taiwan; from Ministry of Science and Technology of Taiwan (MOST 105–2314–B–039–014); and from China Medical University (DMR-106-067 and DMR-107-056). We thank the National Center for Genome Medicine of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, for the technical/bioinformatics support. We also thank Dr. Li Tsai-Chung for her valuable advices in the statistical analysis.

**Author Contributions**
W.L.L. and F.J.T. conceived of and designed the research, J.M.L., W.L.C., M.C.H. and Y.C.H. conducted data collection. W.L.L., C.M.W. and Y.W.C. analyzed the data. W.L.L. wrote the manuscript. All the coauthors have read and approved the final version of the manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-32916-y.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
